2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorderRecruitingPhase 32026-09-15NCT06492616
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32025-10-03NCT05840211